Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 105 entries
Sorted by: Best Match Show Resources per page
Integrative oncology for the whole person: a multidimensional approach to cancer care.

Integrative cancer therapies

Geffen JR.
PMID: 20150226
Integr Cancer Ther. 2010 Mar;9(1):105-21. doi: 10.1177/1534735409355172. Epub 2010 Feb 11.

Today, more than ever before, millions of people are seeking an approach to medicine and health care that is more comprehensive, more holistic and integrative, and more compassionate and sensitive to their needs as a whole person. This is...

Cite
Geffen JR. Integrative oncology for the whole person: a multidimensional approach to cancer care. Integr Cancer Ther. 2010;9(1):105-21doi: 10.1177/1534735409355172.
Geffen, J. R. (2010). Integrative oncology for the whole person: a multidimensional approach to cancer care. Integrative cancer therapies, 9(1), 105-21. https://doi.org/10.1177/1534735409355172
Geffen, Jeremy R. "Integrative oncology for the whole person: a multidimensional approach to cancer care." Integrative cancer therapies vol. 9,1 (2010): 105-21. doi: https://doi.org/10.1177/1534735409355172
Geffen JR. Integrative oncology for the whole person: a multidimensional approach to cancer care. Integr Cancer Ther. 2010 Mar;9(1):105-21. doi: 10.1177/1534735409355172. Epub 2010 Feb 11. PMID: 20150226.
Copy Download .nbib Format: NLM
Oncology trials--the elephant in the room.

Nature reviews. Clinical oncology

Kirk R, Hutchinson L.
PMID: 22456332
Nat Rev Clin Oncol. 2012 Mar 28;9(4):185-6. doi: 10.1038/nrclinonc.2012.33.

No abstract available.

Cite
Kirk R, Hutchinson L. Oncology trials--the elephant in the room. Nat Rev Clin Oncol. 2012;9(4):185-6doi: 10.1038/nrclinonc.2012.33.
Kirk, R., & Hutchinson, L. (2012). Oncology trials--the elephant in the room. Nature reviews. Clinical oncology, 9(4), 185-6. https://doi.org/10.1038/nrclinonc.2012.33
Kirk, Rebecca, and Hutchinson, Lisa. "Oncology trials--the elephant in the room." Nature reviews. Clinical oncology vol. 9,4 (2012): 185-6. doi: https://doi.org/10.1038/nrclinonc.2012.33
Kirk R, Hutchinson L. Oncology trials--the elephant in the room. Nat Rev Clin Oncol. 2012 Mar 28;9(4):185-6. doi: 10.1038/nrclinonc.2012.33. PMID: 22456332.
Copy Download .nbib Format: NLM
The new dimension of oncology. Teleoncology ante portas.

Critical reviews in oncology/hematology

Wysocki WM, Komorowski AL, Aapro MS.
PMID: 15661560
Crit Rev Oncol Hematol. 2005 Feb;53(2):95-100. doi: 10.1016/j.critrevonc.2004.09.005.

Telemedicine is defined as the practice of medicine from a distance, without the doctor's physical presence. Teleoncology consist of telediagnosis, teleconsultation, telepathology, telesurgery, distant help in computer-aided radiotherapy planning and telefollow-up. In this paper, we present the wide range...

Cite
Wysocki WM, Komorowski AL, Aapro MS. The new dimension of oncology. Teleoncology ante portas. Crit Rev Oncol Hematol. 2005;53(2):95-100doi: 10.1016/j.critrevonc.2004.09.005.
Wysocki, W. M., Komorowski, A. L., & Aapro, M. S. (2005). The new dimension of oncology. Teleoncology ante portas. Critical reviews in oncology/hematology, 53(2), 95-100. https://doi.org/10.1016/j.critrevonc.2004.09.005
Wysocki, Wojciech M, et al. "The new dimension of oncology. Teleoncology ante portas." Critical reviews in oncology/hematology vol. 53,2 (2005): 95-100. doi: https://doi.org/10.1016/j.critrevonc.2004.09.005
Wysocki WM, Komorowski AL, Aapro MS. The new dimension of oncology. Teleoncology ante portas. Crit Rev Oncol Hematol. 2005 Feb;53(2):95-100. doi: 10.1016/j.critrevonc.2004.09.005. PMID: 15661560.
Copy Download .nbib Format: NLM
Recent developments and future perspectives of personalized oncology.

Onkologie

Grüllich C, von Kalle C.
PMID: 22286581
Onkologie. 2012;35:4-7. doi: 10.1159/000334825. Epub 2012 Jan 20.

Increasing understanding of molecular carcinogenesis has begun to change paradigms in oncology. On the diagnostic side, the characterization of key mutations and molecular pathways responsible for tumor development and progression has led to the identification of a large number...

Cite
Grüllich C, von Kalle C. Recent developments and future perspectives of personalized oncology. Onkologie. 2012;35:4-7doi: 10.1159/000334825.
Grüllich, C., & von Kalle, C. (2012). Recent developments and future perspectives of personalized oncology. Onkologie, 354-7. https://doi.org/10.1159/000334825
Grüllich, Carsten, and von Kalle, Christof. "Recent developments and future perspectives of personalized oncology." Onkologie vol. 35 (2012): 4-7. doi: https://doi.org/10.1159/000334825
Grüllich C, von Kalle C. Recent developments and future perspectives of personalized oncology. Onkologie. 2012;35:4-7. doi: 10.1159/000334825. Epub 2012 Jan 20. PMID: 22286581.
Copy Download .nbib Format: NLM
Expert opinion: future frontiers and challenges in cancer medicine.

The oncologist

Johnston PG, Lawler M.
PMID: 22639114
Oncologist. 2012;17(5):e3-5. doi: 10.1634/theoncologist.2012-0210.

No abstract available.

Cite
Johnston PG, Lawler M. Expert opinion: future frontiers and challenges in cancer medicine. Oncologist. 2012;17(5):e3-5doi: 10.1634/theoncologist.2012-0210.
Johnston, P. G., & Lawler, M. (2012). Expert opinion: future frontiers and challenges in cancer medicine. The oncologist, 17(5), e3-5. https://doi.org/10.1634/theoncologist.2012-0210
Johnston, Patrick G, and Lawler, Mark. "Expert opinion: future frontiers and challenges in cancer medicine." The oncologist vol. 17,5 (2012): e3-5. doi: https://doi.org/10.1634/theoncologist.2012-0210
Johnston PG, Lawler M. Expert opinion: future frontiers and challenges in cancer medicine. Oncologist. 2012;17(5):e3-5. doi: 10.1634/theoncologist.2012-0210. PMID: 22639114; PMCID: PMC3360916.
Copy Download .nbib Format: NLM
Cancer healthcare: change is the only constant.

Future oncology (London, England)

Holland B, Lake F.
PMID: 24490601
Future Oncol. 2014 Feb;10(2):161-3. doi: 10.2217/fon.13.246.

Ben Holland speaks to Francesca Lake, Managing Commissioning Editor: Ben Holland is a nationally known expert on oncology-specific consulting solutions in the USA. Over the past decade, he has led consulting projects for some of the most prestigious hospitals...

Cite
Holland B, Lake F. Cancer healthcare: change is the only constant. Future Oncol. 2014;10(2):161-3doi: 10.2217/fon.13.246.
Holland, B., & Lake, F. (2014). Cancer healthcare: change is the only constant. Future oncology (London, England), 10(2), 161-3. https://doi.org/10.2217/fon.13.246
Holland, Ben, and Lake, Francesca. "Cancer healthcare: change is the only constant." Future oncology (London, England) vol. 10,2 (2014): 161-3. doi: https://doi.org/10.2217/fon.13.246
Holland B, Lake F. Cancer healthcare: change is the only constant. Future Oncol. 2014 Feb;10(2):161-3. doi: 10.2217/fon.13.246. PMID: 24490601.
Copy Download .nbib Format: NLM
Medical oncology: in search of a definition.

Annals of oncology : official journal of the European Society for Medical Oncology

Numico G, Fasola G.
PMID: 24558026
Ann Oncol. 2014 May;25(5):1075-6. doi: 10.1093/annonc/mdu059. Epub 2014 Feb 20.

No abstract available.

Cite
Numico G, Fasola G. Medical oncology: in search of a definition. Ann Oncol. 2014;25(5):1075-6doi: 10.1093/annonc/mdu059.
Numico, G., & Fasola, G. (2014). Medical oncology: in search of a definition. Annals of oncology : official journal of the European Society for Medical Oncology, 25(5), 1075-6. https://doi.org/10.1093/annonc/mdu059
Numico, G, and Fasola, G. "Medical oncology: in search of a definition." Annals of oncology : official journal of the European Society for Medical Oncology vol. 25,5 (2014): 1075-6. doi: https://doi.org/10.1093/annonc/mdu059
Numico G, Fasola G. Medical oncology: in search of a definition. Ann Oncol. 2014 May;25(5):1075-6. doi: 10.1093/annonc/mdu059. Epub 2014 Feb 20. PMID: 24558026.
Copy Download .nbib Format: NLM
The past, present and future of clinical oncology.

Expert opinion on therapeutic targets

Sun Y.
PMID: 22313250
Expert Opin Ther Targets. 2012 Mar;16:S1-2. doi: 10.1517/14728222.2011.628576. Epub 2012 Feb 07.

No abstract available.

Cite
Sun Y. The past, present and future of clinical oncology. Expert Opin Ther Targets. 2012;16:S1-2doi: 10.1517/14728222.2011.628576.
Sun, Y. (2012). The past, present and future of clinical oncology. Expert opinion on therapeutic targets, 16S1-2. https://doi.org/10.1517/14728222.2011.628576
Sun, Yan. "The past, present and future of clinical oncology." Expert opinion on therapeutic targets vol. 16 (2012): S1-2. doi: https://doi.org/10.1517/14728222.2011.628576
Sun Y. The past, present and future of clinical oncology. Expert Opin Ther Targets. 2012 Mar;16:S1-2. doi: 10.1517/14728222.2011.628576. Epub 2012 Feb 07. PMID: 22313250.
Copy Download .nbib Format: NLM
Patients, pathways, progress.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

García Jordá E.
PMID: 21421457
Clin Transl Oncol. 2011 Mar;13(3):141-2. doi: 10.1007/s12094-011-0632-y.

No abstract available.

Cite
García Jordá E. Patients, pathways, progress. Clin Transl Oncol. 2011;13(3):141-2doi: 10.1007/s12094-011-0632-y.
García Jordá, E. (2011). Patients, pathways, progress. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 13(3), 141-2. https://doi.org/10.1007/s12094-011-0632-y
García Jordá, Enrique. "Patients, pathways, progress." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico vol. 13,3 (2011): 141-2. doi: https://doi.org/10.1007/s12094-011-0632-y
García Jordá E. Patients, pathways, progress. Clin Transl Oncol. 2011 Mar;13(3):141-2. doi: 10.1007/s12094-011-0632-y. PMID: 21421457.
Copy Download .nbib Format: NLM
Personalized cancer medicine.

Onkologie

Marmé D, Hallek M.
PMID: 22286580
Onkologie. 2012;35:2. doi: 10.1159/000335980. Epub 2012 Jan 20.

No abstract available.

Cite
Marmé D, Hallek M. Personalized cancer medicine. Onkologie. 2012;35:2doi: 10.1159/000335980.
Marmé, D., & Hallek, M. (2012). Personalized cancer medicine. Onkologie, 352. https://doi.org/10.1159/000335980
Marmé, Dieter, and Hallek, Michael. "Personalized cancer medicine." Onkologie vol. 35 (2012): 2. doi: https://doi.org/10.1159/000335980
Marmé D, Hallek M. Personalized cancer medicine. Onkologie. 2012;35:2. doi: 10.1159/000335980. Epub 2012 Jan 20. PMID: 22286580.
Copy Download .nbib Format: NLM
Next-generation sequencing in precision oncology: challenges and opportunities.

Expert review of molecular diagnostics

Kruglyak KM, Lin E, Ong FS.
PMID: 24791810
Expert Rev Mol Diagn. 2014 Jul;14(6):635-7. doi: 10.1586/14737159.2014.916213. Epub 2014 May 03.

High throughput gene sequencing is transforming the utilization of genomics in patient care by providing physicians with a powerful tool to aid the diagnosis and management of disease, particularly in precision oncology. As next-generation sequencing (NGS)-based diagnostic assays are...

Cite
Kruglyak KM, Lin E, Ong FS. Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev Mol Diagn. 2014;14(6):635-7doi: 10.1586/14737159.2014.916213.
Kruglyak, K. M., Lin, E., & Ong, F. S. (2014). Next-generation sequencing in precision oncology: challenges and opportunities. Expert review of molecular diagnostics, 14(6), 635-7. https://doi.org/10.1586/14737159.2014.916213
Kruglyak, Kristina M, et al. "Next-generation sequencing in precision oncology: challenges and opportunities." Expert review of molecular diagnostics vol. 14,6 (2014): 635-7. doi: https://doi.org/10.1586/14737159.2014.916213
Kruglyak KM, Lin E, Ong FS. Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev Mol Diagn. 2014 Jul;14(6):635-7. doi: 10.1586/14737159.2014.916213. Epub 2014 May 03. PMID: 24791810.
Copy Download .nbib Format: NLM
Toward a science of tumor forecasting for clinical oncology.

Cancer research

Yankeelov TE, Quaranta V, Evans KJ, Rericha EC.
PMID: 25592148
Cancer Res. 2015 Mar 15;75(6):918-23. doi: 10.1158/0008-5472.CAN-14-2233. Epub 2015 Jan 15.

We propose that the quantitative cancer biology community makes a concerted effort to apply lessons from weather forecasting to develop an analogous methodology for predicting and evaluating tumor growth and treatment response. Currently, the time course of tumor response...

Cite
Yankeelov TE, Quaranta V, Evans KJ, et al. Toward a science of tumor forecasting for clinical oncology. Cancer Res. 2015;75(6):918-23doi: 10.1158/0008-5472.CAN-14-2233.
Yankeelov, T. E., Quaranta, V., Evans, K. J., & Rericha, E. C. (2015). Toward a science of tumor forecasting for clinical oncology. Cancer research, 75(6), 918-23. https://doi.org/10.1158/0008-5472.CAN-14-2233
Yankeelov, Thomas E, et al. "Toward a science of tumor forecasting for clinical oncology." Cancer research vol. 75,6 (2015): 918-23. doi: https://doi.org/10.1158/0008-5472.CAN-14-2233
Yankeelov TE, Quaranta V, Evans KJ, Rericha EC. Toward a science of tumor forecasting for clinical oncology. Cancer Res. 2015 Mar 15;75(6):918-23. doi: 10.1158/0008-5472.CAN-14-2233. Epub 2015 Jan 15. PMID: 25592148; PMCID: PMC4359948.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 105 entries